Elicera Therapeutics AB (publ) (the "Company") has entered into an agreement with DNB Carnegie Investment Bank AB (publ) ("DNB Carnegie") regarding the roles as Certified Adviser and Liquidity provider. DNB Carnegie will take over as Certified Adviser on December 1, 2025 and Liquidity provider on February 2, 2026. Until the respective dates, Mangold Fondkommission AB will continue to act as the Company's Certified Adviser and Liquidity provider.
 

For further information please contact:

Jamal El-Mosleh, CEO, Elicera Therapeutics AB

Phone: +46 (0) 703 31 90 51
jamal.elmosleh@elicera.com

The information was submitted for publication distributed through the contact person above at 16;01 CET on October 23, 2025.

Certified Advisor

Mangold Fondkommission AB

About Elicera Therapeutics AB

Elicera Therapeutics AB  (publ) has developed the patented gene technology platform iTANK that enables the arming of new and existing CAR T-cell therapies targeting aggressive and relapsing cancer forms. Elicera Therapeutics thereby addresses a well-defined and vast market. The company's CAR T-cell therapies have shown a potent effect toward solid tumors which are recognized as particularly difficult to treat and constitute the majority of cancer cases. The company addresses a global multibillion market in cell therapy through its offering of non-exclusive licensing of the iTANK platform to companies in the pharmaceutical industry. Elicera Therapeutics has four internal development projects in immune therapy that separately have the potential to generate substantial value through out-licensing agreements. The company's share is traded on Nasdaq First North Growth Market. For additional information, visit www.elicera.com.